Saturday 17 October 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.72
0.02
−1.15%
Follow BDTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.98 | 8.14 | 8.18 | 8.72 | |
Current Ratio |
7.28 | 8.46 | 8.42 | 8.94 | |
Net Debt/EBITDA |
9.19 | 10.53 | 7.33 | 12.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 1.13 | 0.45 | 0.92 | |
Capex/Depreciation |
0.00 | 0.00 | 0.05 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.18) | (0.12) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.18) | (0.12) | (0.14) | |
Cash per Share |
1.93 | 2.07 | 2.26 | 2.38 | |
Shareholders Equity per Share |
1.68 | 1.82 | 1.97 | 2.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.68 | 1.82 | 1.97 | 2.22 | |
Free Cash Flow |
(7.97) | (10.23) | (6.78) | (7.85) | |
Working Capital |
99.55 | 108.43 | 116.71 | 123.45 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
86.46 | 94.35 | 101.64 | 107.41 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.09 | 2.80 | 2.29 | 1.47 | |
Average Assets |
145.71 | 154.58 | 132.83 | 147.81 | |
Average Common Equity |
114.35 | 122.91 | 97.75 | 111.79 |
Columns are period end dates